{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:18:16Z","timestamp":1774084696754,"version":"3.50.1"},"reference-count":27,"publisher":"Hindawi Limited","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2283,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1111\/j.1365-2710.2008.01004.x","type":"journal-article","created":{"date-parts":[[2009,1,19]],"date-time":"2009-01-19T10:37:09Z","timestamp":1232361429000},"page":"267-276","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and safety of ezetimibe\/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment"],"prefix":"10.1155","volume":"34","author":[{"given":"G.","family":"Derosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. G.","family":"Franzetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. D.","family":"Ragonesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Gadaleta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Scalise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. N.","family":"Piccinni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. F. G.","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","reference":[{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB1","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1001\/archinte.166.21.2307","article-title":"Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials","volume":"166","author":"Thavendiranathan","year":"2006","journal-title":"Archives of Internal Medicine"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB2","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1475-2840-5-20","article-title":"Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins","volume":"5","author":"Tenenbaum","year":"2006","journal-title":"Cardiovascular Diabetology"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB4","first-page":"S318","article-title":"Rising to the challenge of treating high-risk patients","volume":"12","author":"Guthrie","year":"2006","journal-title":"The American Journal of Managed Care"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB5","doi-asserted-by":"crossref","first-page":"53E","DOI":"10.1016\/j.amjcard.2005.06.006","article-title":"Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options","volume":"96","author":"Stone","year":"2005","journal-title":"The American Journal of Cardiology"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.jhh.1002102","article-title":"Use of antihypertensive and lipid-lowering drugs: the management of cardiovascular risk in clinical practice","volume":"21","author":"Di Martino","year":"2007","journal-title":"Journal of Human Hypertension"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.diabres.2006.10.016","article-title":"Undertreatment of cardiovascular risk factors among persons with diabetes in the United States","volume":"77","author":"Malik","year":"2007","journal-title":"Diabetes Research and Clinical Practice"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB8","doi-asserted-by":"crossref","first-page":"61C","DOI":"10.1016\/j.amjcard.2005.12.011","article-title":"Statin safety: an assessment using an administrative claims database","volume":"97","author":"Cziraky","year":"2006","journal-title":"The American Journal of Cardiology"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1185\/030079906X89856","article-title":"Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe","volume":"22","author":"Daskalopoulou","year":"2006","journal-title":"Current Medical Research and Opinion"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB10","volume-title":"The ILIB lipid handbook for clinical practice: dyslipidemia and coronary heart disease","author":"Gotto","year":"2003"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1126\/science.635569","article-title":"The glycosylation of haemoglobin. Relevance to diabetes mellitus","volume":"200","author":"Bunn","year":"1978","journal-title":"Science"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB12","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1464-5491.1999.00166.x","article-title":"A desktop guide to type 2 diabetes mellitus","volume":"16","author":"European Diabetes Policy Group 1999","year":"1999","journal-title":"Diabetic Medicine"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB13","first-page":"121","article-title":"Enzymatische Bestimmung des Gesamtcholesterins mit dem [Enzymatic dosage of total cholesterolemia by Greiner Selective Analyzer (GSA II)]","volume":"15","author":"Klose","year":"1978","journal-title":"Journal of Clinical Chemistry and Clinical Biochemistry"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB14","first-page":"18","volume-title":"Methods of enzymatic analysis","author":"Wahlefeld","year":"1974"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB15","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI103182","article-title":"The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum","volume":"34","author":"Havel","year":"1955","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clinical Chemistry"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB17","volume-title":"Statistical principles in experimental design","author":"Winer","year":"1971"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB18","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2125.2006.02801.x","article-title":"Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage","volume":"63","author":"Poluzzi","year":"2007","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB19","first-page":"S310","article-title":"An assessment of statin safety","volume":"12","author":"McKenney","year":"2006","journal-title":"The American Journal of Managed Care"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0939-4753(04)80008-5","article-title":"Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits","volume":"14","author":"Anfossi","year":"2004","journal-title":"Nutrition, Metabolism, and Cardiovascular Disease"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","article-title":"Genetic risk factors associated with lipid-lowering drug-induced myopathies","volume":"34","author":"Vladutiu","year":"2006","journal-title":"Muscle and Nerve"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB22","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1185\/030079906X132721","article-title":"Lipid-altering efficacy of the ezetimibe\/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients","volume":"22","author":"Catapano","year":"2006","journal-title":"Current Medical Research and Opinion"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB23","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1185\/030079904X2321","article-title":"Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome","volume":"20","author":"Simons","year":"2004","journal-title":"Current Medical Research and Opinion"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB24","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.4065\/81.12.1579","article-title":"Ezetimibe\/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study","volume":"81","author":"Goldberg","year":"2006","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1592\/phco.27.2.309","article-title":"Myopathy associated with atorvastatin-ezetimibe combination therapy","volume":"27","author":"Weffald","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB26","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1185\/030079907X178702","article-title":"Dual cholesterol inhibition with ezetimibe\/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice","volume":"23","author":"Hildemann","year":"2007","journal-title":"Current Medical Research and Opinion"},{"key":"10.1111\/j.1365-2710.2008.01004.x-BIB27","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJMe0807200","article-title":"Ezetimibe and cancer - an uncertain association","volume":"359","author":"Drazen","year":"2008","journal-title":"New England Jurnal of Medicine"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2008.01004.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2710.2008.01004.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:02:51Z","timestamp":1671818571000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2710.2008.01004.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2710.2008.01004.x","relation":{},"ISSN":["0269-4727","1365-2710"],"issn-type":[{"value":"0269-4727","type":"print"},{"value":"1365-2710","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}